SR 8541A
Alternative Names: SR-8541ALatest Information Update: 06 Jan 2025
Price :
$50 *
At a glance
- Originator Stingray Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- Phase I Solid tumours
Most Recent Events
- 20 Nov 2024 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable, Combination therapy) in USA (PO) (NCT06589440)
- 19 Sep 2024 Stingray Therapeutics plans a phase II trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable, Combination therapy) in October 2024 (PO) (NCT06589440)
- 05 Apr 2024 Pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)